TradingMenu expanded
Forge Markets Forge Pro Browse Companies
DataMenu expanded
Forge Data Private Market Index Forge Accuidity Index IPO Stock Tracker
SolutionsMenu expanded
For Institutions For Shareholders For Investors For Companies
InsightsMenu expanded
All Insights Blog Glossary Reports Videos Webinars
Popular Topics
Buying Pre-IPO Shares Selling Pre-IPO Shares Private Market Updates Forge Investment Outlook Startup News Tech IPO Calendar for 2024
AboutMenu expanded
About Us Team Investor Relations People & Culture Careers FAQs
Log In Sign Up
Trading Menu expandedTrading
Forge Markets
Forge Pro
Browse Companies
Data Menu expandedData
Forge Data
Private Market Index
Forge Accuidity Index
IPO Stock Tracker
Solutions Menu expandedSolutions
For Institutions
For Shareholders
For Investors
For Companies
Insights Menu expandedInsights
All Insights
Blog
Glossary
Reports
Videos
Webinars
Popular Topics
Buying Pre-IPO Shares
Selling Pre-IPO Shares
Private Market Updates
Forge Investment Outlook
Startup News
Tech IPO Calendar for 2024
About Menu expandedAbout
About Us
Team
Investor Relations
People & Culture
Careers
FAQs
Trading / Browse Private Companies / Septerna Stock

Septerna Stock

www.septerna.com/Healthcare / BioTech & PharmaFounded: 2022Funding to Date: $225MM

Septerna is a biochemical drug discovery company. With GPCR scientists, Septerna is focused on researching G protein receptors to develop new medicines in the pharmacology field. The company also features drug-screening technology, modular assemblies, and Silico molecule screening. Septerna was founded by Arthur Christopoulos, Jeffrey Finer, Patrick Sexton, and Robert Lefkowitz in 2022 and is headquartered in San Francisco, CA.

Buy or sell Septerna stockLearn more about Septerna IPO

Register To Buy and Sell Shares

For more details on financing and valuation for Septerna, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Septerna’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Septerna.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Septerna investors also invested in these private companies

Casdin Capital
Goldman Sachs Asset Management
Ra Capital Management
Vertex Ventures
Mirae Asset Global Investments
Woodline Partners
Logos Capital
Samsara Biocapital
Soleus Capital
Third Rock Ventures
Deep Track Capital
Catalio Capital Management
Invus Financial Advisors
BVF Partners
Driehaus Capital

Team

Management Team

Jeffrey Finer Ph.D
Co-Founder & Chief Executive Officer
Liz Bhatt
Chief Operating Officer
Samira Shaikhly
Chief People Officer
Ali Masoudi
Co-Founder & Staff Scientist
Arthur Christopoulos Ph.D
Co-Founder
Patrick Sexton Ph.D
Co-Founder
Robert Lefkowitz MD
Co-Founder

Board Members

Abraham Bassan
Samsara BioCapital
Alan Ezekowitz MD
Third Rock Ventures
Jeffrey Tong Ph.D
Third Rock Ventures

Frequently Asked Questions About Septerna’s Stock

plusminus
Can you buy Septerna’s stock?
Septerna is not publicly traded on NYSE or NASDAQ in the U.S. To buy Septerna’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Septerna’s stock?
Yes, you can sell stock of a private company like Septerna. Forge can help you sell your Septerna stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Septerna’s stock price?
Septerna is a privately held company and therefore does not have a public stock price. However, you may access Septerna’s private market stock price with Forge Data.
plusminus
What is Septerna’s stock ticker symbol?
Septerna does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Other companies like Septerna in the BioTech & Pharma sector

Egenesis

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$387.57MM

Colossal Biosciences

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.01B

Prime Medicine

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$1.23B

ADARx Pharmaceuticals

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$827.77MM

Altos Labs

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$6.33B

Tempus

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$8.7B

Pendulum Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$308.05MM

Cytonics

Sector
Healthcare / BioTech & Pharma
 
 

AI Therapeutics

Sector
Healthcare / BioTech & Pharma
Last Round Est. Valuation
$110MM

News Highlights

FIERCEBIOTECH 07/11/2023
Septerna snags $150M series B for pipeline of GPCR therapies tackling hard-to-drug targets
Septerna has secured $150 million in a series B fundraise, money that will go toward two newly unveiled programs including moving its first G-protein-coupled receptor (GPCR) drug into the clinic.

Trending Companies

Frequently Asked Questions

Updated on: Apr 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.